Complement Activation in Maternal and Placental Pathology of Preeclampsia
- 3 June 2026
- journal article
- Published by Wolters Kluwer Health in Hypertension
- Vol. 83 (8)
Abstract
BACKGROUND: Preeclampsia is a multifactorial, pregnancy-related disorder characterized by new-onset hypertension and proteinuria, with distinct early- and late-onset forms. Although complement dysregulation has been implicated in the pathogenesis of preeclampsia, its causal role remains unclear. In mice, Crry (complement receptor 1-related protein Y) functions as a critical complement regulator at the fetal-maternal interface. Because complete Crry deficiency is embryonically lethal, direct in vivo investigation of complement activation in pregnancy has been challenging. METHODS: We generated a placenta-specific, doxycycline-inducible short hairpin RNA mouse model in which Crry expression can be downregulated in a dose-dependent manner. This system employs Cyp19-driven Cre recombinase and a tetracycline-inducible gene expression system regulatory cassette, enabling precise temporal and spatial control of Crry suppression and restricting complement activation specifically to the placenta. RESULTS: We found that early gestation placental complement activation impairs maternal cardiac and hepatic adaptation, reduces placental efficiency, and causes fetal growth restriction—features consistent with early-onset preeclampsia. Delayed complement activation produces a phenotype resembling late-onset preeclampsia, characterized by maternal hypertension without placental pathology. In the early-onset-like phenotype, fetal growth restriction is accompanied by placental glycogen storage deficiency and impaired endocrine function. Maternal glucose metabolism remains intact; however, compensatory changes in lipid metabolism occur, although these adaptations are insufficient to prevent fetal growth restriction. CONCLUSIONS: This model demonstrates that the timing of placental complement activation determines whether pregnancy develops early- or late-onset-like features. These findings provide mechanistic insight into how complement dysregulation contributes to the spectrum of preeclampsia pathology and establish a powerful experimental platform for studying disease mechanisms and evaluating therapeutic strategies.Keywords
This publication has 60 references indexed in Scilit:
- Animal models of preeclampsia: investigating pathophysiology and therapeutic targetsAmerican Journal of Obstetrics and Gynecology, 2021
- Pathophysiology of placental-derived fetal growth restrictionAmerican Journal of Obstetrics and Gynecology, 2018
- Incidence of preeclampsia: risk factors and outcomes associated with early- versus late-onset diseaseAmerican Journal of Obstetrics and Gynecology, 2013
- Elevated complement factor C5a in maternal and umbilical cord plasma in preeclampsiaJournal of Reproductive Immunology, 2013
- The complotype: dictating risk for inflammation and infectionTrends in Immunology, 2012
- Activation of the complement system in normal pregnancy and preeclampsiaMolecular Immunology, 2010
- Expression of Cre recombinase in early diploid trophoblast cells of the mouse placentaGenesis, 2007
- Origin and characteristics of glycogen cells in the developing murine placentaDevelopmental Dynamics, 2006
- Shared and disparate components of the pathophysiologies of fetal growth restriction and preeclampsiaAmerican Journal of Obstetrics and Gynecology, 2006
- Placental angiogenic growth factors and uterine artery Doppler findings for characterization of different subsets in preeclampsia and in isolated intrauterine growth restrictionAmerican Journal of Obstetrics and Gynecology, 2006